Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Bioavailability of Subcutaneous XmAb7195 in Healthy and Atopic Subjects
NCT02881853Phase 1Completed
- Sponsor
- Xencor
- Start
- Aug 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xmab7195 in atopic disease (9 arms), sponsored by Xencor. Primary endpoint: Bioavailability of SC XmAb7195 at Day 50. Started Aug 2016; status: completed.
02
Drugs
xmab7195
03
Conditions
atopic disease
Beyond the preview
Go deeper on NCT02881853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881853.